|Awarded On||February 19, 2020|
|Title||Nucleostemin: A New Tumor Addictive Mechanism, Outcome Predictor, and Therapeutic Target for Hepatocellular Carcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Robert Tsai|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Liver cancer is projected to become the third leading cause of cancer-related death by 2030. Moreover, it has created major issues of health disparity in the US, affecting disproportionately the Mexican American population in south Texas. To date, patients with unresectable liver cancer remain almost untreatable, with a 5-year survival rate below 15%. The challenges in treating unresectable liver cancer reside in its high resistance to chemo/radiation therapies and diverse underlying causes. Recent studies, which include some of ours, have determined that in spite of the many events that drive tumor development, they all seem to converge on a few protective mechanisms that allow tumor cells ...